C-reactive protein (CRP) is the prototypical acute phase reactant, increasing in blood concentration rapidly and several-fold in response to inflammation. Recent evidence indicates that CRP has an important physiological role even at low, baseline levels, or in the absence of overt inflammation. For example, we have shown that human CRP inhibits the progression of experimental autoimmune encephalomyelitis (EAE) in CRP transgenic mice by shifting CD4 + T cells away from the TH1 and toward the TH2 subset. Notably, this action required the inhibitory Fcγ receptor IIB (FcγRIIB), but did not require high levels of human CRP. Herein, we sought to determine if CRP's influence in EAE might be explained by CRP acting on dendritic cells (DC; antigen presenting cells known to express FcγRIIB). We found that CRP (50 µg/ml) reduced the yield of CD11c + bone marrow-derived DCs (BMDCs) and CRP (≥5 μg/ml) prevented their full expression of major histocompatibility complex class II and the co-stimulatory molecules CD86 and CD40. CRP also decreased the ability of BMDCs to stimulate antigen-driven proliferation of T cells in vitro. Importantly, if the BMDCs were genetically deficient in mouse FcγRIIB then (i) the ability of CRP to alter BMDC surface phenotype and impair T cell proliferation was ablated and (ii) CD11c-driven expression of a human FCGR2B transgene rescued the CRP effect. Lastly, the protective influence of CRP in EAE was fully restored in mice with CD11c-driven human FcγRIIB expression. These findings add to the growing evidence that CRP has important biological effects even in the absence of an acute phase response, i.e., CRP acts as a tonic suppressor of the adaptive immune system. The ability of CRP to suppress development, maturation, and function of DCs implicates CRP in the maintenance of peripheral T cell tolerance.
number of pattern recognition proteins. Among these C-reactive protein (CRP) is the prototype; it is maintained at low levels in normal sera (1-5 µg/ml) (1), but can reach upwards of ~500 μg/ml during inflammation (2) . CRP's ability to activate complement, opsonize microbes, bind to phosphatidylserine on apoptotic cells, and bind Fc receptors is well known (2) (3) (4) and these biological actions have been studied extensively in the context of CRP's upregulation during inflammation. Increasing evidence indicates that CRP also exerts important biological influences even when its levels remain low as in healthy individuals and when it is only slightly raised as in aging individuals (4) .
Previously, we have shown that human CRP transgenic mice (CRPtg) are resistant to experimental autoimmune encephalomyelitis (EAE), a disease comparable to human multiple sclerosis (MS) i.e., they have delayed onset of disease and milder clinical symptoms compared to wild type (WT) mice. Notably, despite the ability of CRPtg to mount a robust human CRP acute phase response, this protection does not require high levels of human CRP. We initially attributed CRP's protective action in EAE to inhibition of encephalitogenic T cells, since in vitro CRP reduced T cell proliferation and shifted their cytokine production toward a less noxious TH2 profile (5) . Our subsequent studies demonstrated that FcγRIIB −/− mice, which lack expression of this inhibitory receptor, were refractory to CRP's protective action (6), but we did not identify the FcγRIIB-expressing cell(s) that CRP relied upon. Herein, we demonstrate that CRP impairs the development of bone marrow (BM) cells into CD11c + dendritic cells (DCs), professional antigen presenting cells that express ample FcγRIIB (7) , are paramount for robust T cell responses (8) , and are known to contribute to EAE/MS (9, 10, 11) .
At doses as low as 5 µg/ml, CRP significantly prohibited bone marrow-derived DCs (BMDC) activation/maturation in response to stimulation with lipopolysaccharide (LPS), and impaired the ability of BMDCs to promote antigen-specific T cell proliferation. These suppressive actions of CRP were not evident using FcγRIIB −/− BMDCs, but BMDCs from FcγRIIB −/− mice genetically reconstituted to express a CD11c-driven human FcγRIIB transgene (cd11cFcγRIIB hu ) were responsive to CRP, i.e., CRP prohibited their activation/maturation in response to LPS and suppressed their ability to promote T cell proliferation. As we previously reported, CRPtg were more resistant to EAE compared to WT, whereas CRPtg lacking expression of endogenous FcγRIIB (FcγRIIB −/− /CRPtg), were not. For the latter, however, expression of the CD11c-specific human FcγRIIB transgene fully reconstituted human CRP-mediated protection from EAE.
Based on these new findings, we propose that CRP acts as an endogenous down-regulator of DC development and activation/ maturation, thereby acting as a brake on T cell mediated immunity and shifting the balance toward tolerance. Given that many of the effects of CRP on DCs were observed using ≤10 μg/ml, it is likely that even modest elevation of blood CRP-like that associated with aging (12)-is sufficient to significantly affect T cell tolerance.
MaTerials anD MeThODs

Mice
Our human CRPtg have been fully described elsewhere (13, 14) . In brief, CRPtg (C57BL/6 background) carry a 31-kb human DNA fragment encoding the CRP gene and all the cis-acting elements required for tissue specificity and acute phase inducibility, while the trans-acting factors required for its human-like pattern of regulation are conserved from mouse to man (13, 14) . Consequently, unlike WT, CRPtg exhibit a robust human CRP acute phase response during inflammation. FcγRIIB deficient mice (FcγRIIB −/− ; B6.129S4-Fcgr2b tm1TtK N12) (15) were purchased from Taconic Farms (Germantown, NY). 2D2 mice [C57BL/ 6-Tg(Tcra 2D2, Tcrb 2D2) 1Kuch/J] (16) are transgenic for a T cell receptor (TCR) that recognizes residues 35-55 of myelin oligodendrocyte glycoprotein (MOG35-55) and were purchased from Jackson Laboratories (Bar Harbor, ME, USA; JAX 006912). OT-II mice [B6.Cg-Tg(Tcra Tcrb)425Cbn/J] (17) are transgenic for a TCR that recognizes residues 323-339 of ovalbumin (OVA323-339) and were purchased from Jackson Laboratories (Bar Harbor, ME, USA; JAX 004194). FcγRIIB −/− mice expressing a human FCGR2B transgene driven by a mouse CD11c minimal promoter (cd11cFcγRIIB hu ) were generated herein and are fully described in the Section "Results. " To date, no embryonic lethality or unusual phenotype has been observed for cd11cFcγRIIB hu . C57BL/6 mice (WT) were obtained from the Jackson Laboratories (Bar Harbor, ME, USA; JAX 000664). All mice were housed in the same vivarium at constant humidity (60 ± 5%) and temperature (24 ± 1°C) with a 12-h light cycle (6:00 a.m. to 6:00 p.m.), and maintained ad libitum on sterile water and regular chow (Harlan Teklad). Mice were 8-12 weeks old when used and both sexes were combined unless specifically noted. All animal use protocols were approved by the Institutional Animal Care and Use Committees at the University of Alabama at Birmingham and were consistent with the Guide for the Care and Use of Laboratory Animals; Eighth Edition (NIH Academies Press, 2011).
BMDc cultures
Bone marrow progenitors were grown under conditions known to drive DC generation and expansion (18, 19) . Briefly, BM was harvested from femurs, the red blood cells lysed (Hybri-Max Red Blood Cell Lysing Buffer; Sigma, Salem, MA, USA), and the marrow passed through a 70 µM cell strainer and brought to single-cell suspension in RPMI 1640 (Gibco, Grand Island, NY) containing 5% fetal bovine serum (Gibco), 1% Penicillin/ Streptomycin (Gibco), 2 mM GlutaMAX™ (Invitrogen), non-essential amino acids (Gibco), 55 µM β-mercaptoethanol (Gibco), and 20 ng/ml granulocyte macrophage-colony stimulating factor (Shenandoah Biotechnology, Warwick, PA, USA). BM progenitors were then added to 12-well tissue culture plates (1 × 10 6 cells in 1 ml per well) that were incubated at 37°C, 5% CO2 for 7 days. The culture medium was replaced on days 3 and 5. On day 5, cells were exposed to 50 µg/ml of highly purified human CRP (endotoxin and azide-free CRP from US Biological; Salem, MA, USA), purified chicken OVA323-339 peptide (MISC-011; CPC Scientific, San Jose, CA, USA), or purified MOG35-55 peptide (12668-01; Biosynthesis Inc., Lewisville, TX, USA). OVA323-339 and MOG35-55 loaded BMDCs were subsequently used in BMDC:T cell co-cultures with OT-II and 2D2 T cells, respectively, as described below. To trigger BMDC maturation in some experiments LPS from Escherichia coli, serotype 055:B5 (Sigma Aldrich) was added (1 µg/ml) on day 6. Alternatively, culture medium was supplemented with 100 ng/ml interleukin-4 (IL-4; Shenandoah Biotechnology, Warwick, PA, USA 
T cells and BMDc:T cell cocultures
From OT-II and 2D2 mice, the spleens and lymph nodes (axillary, brachial, inguinal) were harvested and mechanically homogenized, the red blood cells lysed, and the homogenate passed through a 70 µM cell strainer, and brought to single-cell suspension in media at 1 × 10 8 cells/ml. CD4 + T cells were enriched by negative selection according to the manufacturer's guidelines using a kit from StemCell Technologies (Vancouver, BC, Canada). Enriched CD4 + T cells were then stained for 20 min with 1 µM CellTrace™ carboxyfluorescein succinimidyl ester (CFSE; Invitrogen, Eugene, OR, USA). BMDCs, cultured as described above, were treated with MOG35-55 or OVA323-339 peptide on day 6. On day 7, the peptide-loaded BMDCs were mixed with the freshly isolated and CFSE-stained CD4 + T cells (1:5 ratio in triplicate), placed into 96-well round bottom plates, and incubated for 3 days before analysis of CD4 + T cell proliferation (dilution of CFSE). BMDC:T cell co-cultures exposed to plate-bound anti-CD3ε and soluble anti-CD28 antibodies (both from Biolegend, San Diego, CA, USA) served as positive controls.
antibodies and Flow cytometry
Cells were washed with PBS, spun down at 300 × g for 5 min at 4°C, stained with the viability dye eFluor 780 (eBioscience, San Diego, CA, USA) for 30 min at room temperature, fixed in Fixation Buffer (Biolegend, San Diego, CA, USA) for 10 min at room temperature, blocked with anti-mouse CD16/32 (clone 93; eBioscience) at 4°C for 15 min, and stained with specific antibodies at 4°C for 30 min. For BMDCs, we used anti-mouse CD11c (clone N418), MHC class II IA/IE (clone M5/114.15.2), CD40 (clone HM40-3), CD80 (clone 16-10 A1), CD86 (clone GL-1) (all from Biolegend), and FcγRIIB (clone AT 130-5, Bio Rad, Hercules, CA, USA), and anti-human FcγRIIB (clone AT 10, AbD Serotec, Raleigh, NC, USA). For T cells we used anti-mouse CD4 (clone RM4-5) (Biolegend). Stained and labeled cells were run on a BD LSR-II cytometer and the acquired data analyzed using BD FACSDiva version 6.1.3 and FlowJo version 10.3. For all gating analyses, debris was gated out using a FSC by SSC dot plot, followed by selection of single cells using a SSC-A by SSC-H dot plot, and live cells were selected based on the viability dye eFluor 780 dot plot. For assessment of T cell proliferation (CFSE dilution), the bounds for the CD4 + CFSE + "parents" gate was determined using unstimulated T cells and the bounds for the "progeny peaks" were based on anti-CD3ε/anti-CD28 stimulated T cells (see Figure 3A) . As T cells divide, the progeny:parent ratio increases.
experimental autoimmune encephalomyelitis
Experimental autoimmune encephalomyelitis was induced as we described previously (5, 6, 20) . Briefly, 10-12-week-old mice were immunized subcutaneously with 150 µg MOG35-55 emulsified in Freund's complete adjuvant plus 400 µg heat-killed Mycobacterium tuberculosis (Difco, Detroit, MI, USA). On days 0 and 2, mice received an intraperitoneal injection of 200 ng pertussis toxin (List Biological Laboratories, Campbell, CA). For 30 days thereafter the development of EAE was monitored daily. EAE symptoms were scored on a clinical scale ranging from 0 to 6 as follows: 0, asymptomatic; 1, loss of tail tone; 2, flaccid tail; 3, incomplete paralysis of one or two hind limbs; 4, complete hind limb paralysis; 5, moribund (at which case the mouse was humanely euthanized); 6, dead. For mice that developed EAE, the day of onset was defined as the first of two consecutive days, wherein the clinical score was ≥2.
statistical analysis
Raw data were pooled and are expressed graphically as the mean ± SEM or SD, as noted. Group comparisons were done using one-way analysis of variance (ANOVA) followed by post hoc Bonferroni's and Tukey's multiple comparison tests, or using linear trends tests. Differences were considered significant when p was <0.05. For EAE, the maximum clinical score achieved by each animal during the 30-day observation period was used to calculate the average maximum clinical score (a measure of severity). To study the time-course of disease, average clinical scores were calculated and plotted daily for each group of mice, and cumulative disease index (CDI) was calculated by area under the curve analysis. Statistical analyses were done using GraphPad Prism version 7.00.
resUlTs crP suppresses generation and Maturation of BMDcs
We first examined the influence of human CRP on the generation of DCs from BM progenitors. On day 7 of culture, nearly 90% of all cells were viable (dashed horizontal lines in Figure 1A ) and the cultures routinely achieved a yield of nearly 75% BMDCs (dashed horizontal line in Figure 1B) . Whether CRP at 10 or 100 µg/ml was added on day 0 or 6 of culture it had no significant effect on cell viability ( Figure 1A ). CRP treatment also had no effect on the proportion of early apoptotic, late apoptotic, and necrotic BM cells (data not shown). However, CRP treatment did significantly decrease (by 10-15%) the proportion of CD11b 
CD11c
+ BMDCs that developed ( Figure 1B) . Notably, when CRP was added at the initiation of culture, the inhibitory effect on the final yield of BMDCs was strongest ( Figure 1B) and was dosedependent ( Figure 1C) . These results show that while CRP has no significant influence on the viability of cultured BM progenitors, it does significantly impede the generation of CD11b + CD11c + BMDCs in both a temporal and dose-dependent manner. BMDCs was reduced in a dose-dependent fashion by CRP (1-100 µg/ml) added on day 0 of culture. The symbols indicate the results of one-way analyses of variance with Tukey's multiple comparisons tests compared to cultures not treated with CRP, p < 0.005 (**) (n = 3-9 per group).
FigUre 1 | Continued CD40, and CD80 (Figure 2A) , whereas treatment of immature BMDCs with LPS (1 µg/ml) significantly upregulated these markers (Figure 2A) , indicative of BMDC maturation. While CRP did not trigger BMDC maturation, CRP did significantly inhibit the LPS-triggered increase in surface expression of MHC class II and the co-stimulatory markers, CD86 and CD40 (Figure 2A) . Also, the suppressive effect of CRP on LPS-triggered BMDC maturation was dose-dependent, as evidenced by a stepwise reduction of MHC class II, CD86, and CD40 ( Figure 2B ). This suppressive effect was specific as CRP had no effect on the expression of CD80, CD11b, or CD172a ( Figure 2B) . Finally, BMDCs treated with LPS (1 µg/ml) robustly produced both the T cell suppressive cytokine IL-10 and the T cell stimulatory cytokine IL-12p70 (225.7 ± 8.8 and 1245.8 ± 191.0 ng/ml, respectively), but the production of both cytokines was significantly suppressed by CRP (no detectable IL-10 and 773.2 ± 13.2 ng/ml IL-12p70; p < 0.05, t-tests). These data demonstrate that CRP dose-dependently prohibits LPS-triggered activation/maturation of BMDCs and limits their production of IL-10 and IL-12p70, cytokines with pleiotropic effects in immunoregulation.
crP inhibits BMDc-Mediated stimulation of antigen-specific T cell Proliferation
We next sought to determine if the observed effects of CRP on BMDC activation/maturation phenotype and cytokine production affects their T cell stimulatory function. We found that CRP (1-100 µg/ml) had no significant effect on the proliferation of OT-II T cells co-cultured with BMDCs in the absence of any stimulus (Figure 3B ; nil) or in the presence of T cell activating antibodies ( Figure 3B ; CD3/CD28). Importantly, however, when BMDCs loaded with OVA323-339 peptide were used as APCs, the addition of CRP caused a dose-dependent inhibition of OT-II T cell proliferation (Figure 3B; OVA) . Using the MOG TCR-transgenic model (2D2) we obtained similar results, i.e., CRP (50 µg/ml) significantly inhibited the proliferation of 2D2 T cells co-cultured with BMDCs loaded with MOG35-55 peptide ( Figure 3C ). These data confirm that CRP's prohibition of BMDC activation/maturation and cytokine production reduces their ability to stimulate antigen-specific T cell proliferation. The fact that in both model systems, CRP had no effect on T cells directly stimulated with anti-CD3ε/anti-CD28 antibodies shows that CRP's influence on T cell proliferation must be via its actions on BMDCs.
Next, we assessed the influence of CRP on activation/maturation of BMDCs. Treating immature BMDCs with CRP (50 µg/ml) had no effect on their surface expression of MHC class II, CD86, FcγRIIB −/− BMDCs ( Figure 4A) . Like for WT BMDCs, expression of IL-10 by LPS-treated FcγRIIB −/− BMDCs (308.5 ± 12.5 ng/ml) was lowered by CRP (69.6 ± 8.7 ng/ml). However, unlike for WT BMDCs, for FcγRIIB −/− BMDCs treated with LPS the amount of IL-12p70 produced (948.9 ± 25.3 ng/ml) was not reduced by CRP (1017.1 ± 51.6 ng/ml). These findings strongly suggest that FcγRIIB expression is required for CRP to prohibit LPS-induced activation/ maturation of BMDCs and to suppress production of the T cell stimulatory cytokine IL-12p70. As expected, when MOG33-55 peptideloaded FcγRIIB −/− BMDCs were used as APCs, CRP (50 µg/ml) did not impair their proliferation (Figure 4B) . In our hands, FcγRIIB −/− BMDCs did not stimulate OT-II T cell proliferation even when loaded with OVA323-339 (data not shown), precluding us from assessing if CRP requires FcγRIIB in the OT-II model system. Nevertheless, the results from the 2D2 model confirmed that CRP's ability to prohibit BMDC stimulation of an antigen-specific T cell response is facilitated by FcγRIIB expressed on BMDCs. We generated cd11cFcγRIIB hu BMDCs and confirmed that they upregulated expression of MHC class II, CD86, CD40, and CD80 after LPS-triggered activation/maturation ( Figure 6A ) and that CRP alone had no effect on expression of these markers ( Figure 6A) . Expression of human FcγRIIB partly reconstituted the CRP prohibitory effect on BMDC maturation, i.e., upon LPS-stimulation, CRP prohibited the expression of MHC class II and CD40 (Figure 6A) . CRP inhibited IL-10 production by LPSstimulated cd11cFcγRIIB hu BMDCs (459.4 ± 3.1 ng/ml without CRP and no detectable amounts with CRP), but not IL-12p70 production (485.9 ± 94.8 ng/ml and 689.9 ± 235.9 ng/ml without or with CRP, respectively). Although the effect was not significant (ns), when MOG35-55 peptide-loaded cd11cFcγRIIB hu BMDCs were used DCs using FcγRIIB −/− BM to test if CRP's influence on BMDC phenotype and function required FcγRIIB. Like the expression on immature WT BMDCs (Figure 2A) , expression of MHC class II, CD80, CD40, and CD86 on immature FcγRIIB −/− BMDCs was unaffected by CRP alone (50 µg/ml), and LPS triggered their increase ( Figure 4A) . However, in stark contrast to its effect on LPS-matured WT BMDCs (Figure 2A) , CRP did not impair the LPS-triggered upregulation of MHC class II, CD86, and CD40 by as APCs, their ability to stimulate the proliferation of 2D2 T cells was reduced by CRP ( Figure 6B ). These data generally support the premise that CRP's influence on DCs requires their expression of FcγRIIB, since some of the effects of CRP on FcγRIIB −/− BMDCs are recovered by expression of human FcγRIIB. Interestingly, although reconstitution of FcγRIIB −/− BMDCs with human FcγRIIB restored their ability to promote OVA323-339-driven OT-II T cell proliferation, CRP (50 µg/ml) did not have a significant effect (data not shown).
human FcγriiB supports human crP's Protective actions in eae
We had previously shown that CRPtg undergoing EAE have delayed onset and reduced severity of disease compared to WT and that this beneficial effect of CRP is FcγRIIB-dependent (5, 6, 20, 25) , and herein we provide new evidence that this FcγRIIB-dependency extends to BMDCs in vitro. Moreover, although not all the observed effects of human CRP on BMDCs were supported by human FcγRIIB, CD11c-specific expression of human FcγRIIB was sufficient to fully reconstitute human CRP's beneficial actions in EAE (Figure 7 ; Table 1 ). Given that human CRP can utilize human FcγRIIB expressed by CD11c + cells in transgenic mice, it is possible that the same or a similar CRP→FcγRIIB pathway operates in humans to regulate tolerance and prevent autoimmunity.
DiscUssiOn
Previously, we showed that human CRP protects CRPtg mice from EAE triggered either directly by immunization with MOG or indirectly by the transfer of MOG-specific T cells (5, 20, 25) and that this protection was FcγRIIB-dependent manner (6) . Although human CRP can have direct effects on T cells (25) , the initial evidence of CRP inhibiting EAE suggested that CRP most likely conferred protection by acting on an intermediary APC. This study provides strong evidence to this effect, i.e., in vivo human CRP protects mice from EAE by acting on CD11c + FcγRIIB-expressing DCs. We propose that the beneficial effect of Table 1 for details). The inset shows the course of EAE in CRPtg compared to wild type from a separate experiment (n = 6-10 mice per group).
transgenically expressed human CRP in EAE, and perhaps other T cell-mediated diseases like lupus and collagen-induced arthritis (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) , is achieved via its capacity to inhibit DC development and function, thereby diminishing the stimulation of pathogenic T cells.
Our in vitro data reveal several separate, but likely additive, mechanisms by which CRP impacts the T cell stimulating actions of DCs. First, CRP dose-dependently decreased the proportion of BM progenitors that developed into BMDCs, suggesting that CRP influences the fate of hematopoietic stem cells. Native pentameric CRP is likely required for this effect as heat denatured CRP did not have any effect (data not shown). Furthermore, CRP did not significantly affect early or late apoptosis or necrosis during the course of BM culture, demonstrating that CRP binding to phosphatidylserine on dying cells does not play a significant role and that CRP's influence is likely not due to selective killing of certain BM progenitors. Indeed, in separate studies we have also observed that CRP dose-dependently promotes the development of myeloid-derived suppressor cells (MDSC) at the expense of DCs ( Figure S1 in Supplementary Material), and that the spleens of healthy CRP knockout mice (27) Figure S2 in Supplementary Material). The mechanism by which CRP alters myeloid progenitor cell developmental fate is still under investigation, but the fact that CRP shifts the myeloid balance away from DCs (which can promote T cell proliferation) and toward MDSCs (which can suppress it) directly implicates CRP in the regulation of the balance between adaptive immunity and tolerance. Second, CRP dose-dependently prohibits the LPStriggered (TLR4-triggered) activation/maturation of BMDCs as evidenced by its ability to limit expression of MHC class II and costimulatory markers. Notably, CRP had no effect in the absence of a maturation signal (i.e., immature BMDCs) or in the presence of the TLR9 agonist CpG oligodeoxynucleotides (data not shown). This implies that in vivo CRP attenuates the responses of mature DCs in the periphery (i.e., those not participating in central tolerance) and does not impact immature DCs. Third, CRP impairs the production of IL-10 and IL-12p70 by BMDCs, two pleiotropic cytokines that can suppress (29) or promote (30) T cell functions, respectively. Fourth, CRP inhibited the ability of peptide-loaded mature BMDCs to stimulate antigen-driven T cell proliferation. Unexplored was whether CRP impairs the ability of BMDCs to uptake, process, and present antigen, but others have shown that CRP can also impact these processes (31) (32) (33) .
We previously showed that in the absence of FcγRIIB, human CRP cannot protect mice against EAE (6) . That observation led us here to test whether the CRP-responsive, FcγRIIB-expressing cell that might promote CRP's beneficial effects in EAE are DCs (7) . In preliminary studies, we showed that CRP dose-dependently decreased the yield of both WT and FcRγ −/− CD11c + BMDCs, but not FcγRIIB −/− ones ( Figure S3 in Supplementary Material). In alignment with those initial data, we showed herein that FcγRIIB −/− BMDCs maintain their ability to mature in response to LPS and to subsequently stimulate 2D2 T cell proliferation when loaded with MOG35-55, but are refractory to inhibition by CRP. Importantly, in the absence of FcγRIIB expression, CRP was unable to downregulate BMDC production of the T cell stimulating cytokine IL-12p70. These findings highlight the importance of FcγRIIB for the inhibitory action of CRP on the development, maturation, cytokine production, and antigen-specific T cell stimulatory function of BMDCs. Since, human CRP can bind both mouse and human FcγRs in vitro and in vivo (2, 21), we generated a mouse completely deficient in endogenous mouse FcγRIIB, but expressing human FCGR2B on CD11c + cells. Using bone marrow from these cd11cFcγRIIB hu mice we showed that human CRP utilized human FcγRIIB to evoke impairment of BMDC activation and T cell stimulating function, but not to regulate IL-12p70 production. Nevertheless, CRP protection from EAE was fully reconstituted in CRPtg/cd11cFcγRIIB hu mice. We recognize that mouse CD11c, and, therefore, human FcγRIIB in the cd11cFcγRIIB hu mice, might be expressed at low levels on cell types other than DCs and that other DC subtypes may not express CD11c at all [e.g., plasmacytoid DCs and DCs with tolerogenic phenotypes (34) ]. Nevertheless, this study is the first to show that human CRP interaction with human FcγRIIB expressed in vivo on CD11c
+ cells can modulate EAE. We suspect that CRP regulates the generation and actions of DCs in the periphery (i.e., those not directly involved in central tolerance), thereby limiting the activation of auto-reactive T cells especially in the setting of tolerance breakdown. Withal, CRP promotes the number and generation of myeloid-derived suppressor cells (MDSCs) [ Figure S1 in Supplementary Material (35) ], a cell type known to potently suppress T cell proliferation (36) . Simply by modulating the myeloid lineage development away from DCs and toward MDSCs, CRP could thus profoundly impact T cell immunity and the maintenance of peripheral tolerance. This role is unlikely to be restricted to EAE/MS and should also be manifest in the setting of immunosenescence and aging, for example [reviewed in Ref. (37) ]. Indeed, some of the prominent features of immunosenescence are inflammation, decreased T cell numbers, and decreased naïve and memory T cell responsiveness (37, 38, 39) , and in the aged, inflammaging can contribute to dysregulated DC responses and a consequent breakdown of tolerance that can predispose them to autoimmunity (40, 41) . We propose that in this context, modest elevation of CRP due to biological aging (12) might act as a tonic suppressor of DC activation and thus limit autoreactivity.
eThics sTaTeMenT
This study was carried out in accordance with the recommendations of the Guide for the Care 
